AzTrials
AzTrials

Breast Cancer ScreeningNCT05960188

Project 1: Self-Triage by 2D Full-field Digital Mammography or Synthetic Images

A study testing AI Opinion in people with Breast Cancer Screening, run by Brigham and Women's Hospital at 1 site in United States.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

One method of breast cancer screening involves radiologists reading digital tomosynthesis (DBT) images. DBT consists of a 3D stack of x-ray "slices" through the breast. The exam is accompanied by a 2D image like a standard mammogram, a single x-ray of the breast. In a screening setting, most cases are normal. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Breast Cancer Screening
What is being tested?
AI Opinion
How many people
16 participants
Where
1 siteUnited States
Study dates
1 Mar 2023to 1 Sep 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Must be Radiologists or radiology trainees
  • some experience reading mammography.

Who cannot join

  • acuity less than 20/25 with correction

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Visual Attention Lab / Brigham and Women's Hospital

    Boston, Massachusetts, 02215

Other trials in United States

About this study

Official title: Project 1: Self-Triage by 2D Full-field Digital Mammography or Synthetic Images NOTE: Note, This is One Study Under Study ID 386408 Project 1: Radiologist Studies

One method of breast cancer screening involves radiologists reading digital tomosynthesis (DBT) images. DBT consists of a 3D stack of x-ray "slices" through the breast. The exam is accompanied by a 2D image like a standard mammogram, a single x-ray of the breast. In a screening setting, most cases are normal. Sometimes it is obvious that a case is normal from a quick look at the 2D image. It would speed up the process of screening if readers could dismiss a clearly normal case on the basis of the 2D image, alone, without looking at the DBT images. Obviously, the investigators would only want to "triage" cases in this way if the investigators were almost perfectly sure that no cancers would be missed. In this study, the investigators look at radiologist's willingness to triage cases and on the accuracy of their answers. In addition, the investigators ask about the impact of an Artificial Intelligence (AI) opinion. Would it be possible to triage an image on the basis of the AI opinion, alone?

Radiologists will look at each case for up to five seconds and offer an opinion (on a 1-10 scale) about how sure they are that a case is normal. Next, they will see the opinion of the AI. Finally, they will say (using a 1-10) scale, how willing they would be for the AI to triage this case without human intervention.

This study is the start of an effort to understand the conditions under which radiologists might be willing to declare a case "normal" with little or no human examination.

Read the detailed description

NOTE: This registration is linked to a Human Subjects registration in ASSIST. That, in turn, is part of an NCI Grant, CA207490. The grant describes many proposed experiments and notes that many others might be done as follow-up studies. At the suggestion of the NIH, the investigators grouped these studies into three "studies", each covering multiple experiments. The experiment described here is part of "Study ID 386408 Project 1: Radiologist Studies". It is not possible to register a set of experiments through the PRS system in CT.gov and it is not possible to file an annual report for the grant (RPPR) without an NCT number for projects that have started collecting participants. Accordingly, the investigators are describing one experiment here that would be part of the "Project 1" bundle of studies.

The core idea of Project 1 is that it might be possible for Os to reliably eliminate a set of cases in screening mammography after just a brief look at a 2D image or, potentially, after an AI system takes a brief look at the image. That is, the clinician and/or the AI would look at the image and know "for sure" there is nothing there and would be willing to dismiss or "triage" the case on the basis of this brief look. If the reader was not completely sure, the case would get more scrutiny.

As a start at looking at this issue, the investigators wanted to estimate how willing clinicians would be to triage a case and how they would interact with an AI that was asked to triage cases. A challenge for any implementation of triage will be to get clinicians (to say nothing of lawyers, et al) to accept the idea of not looking at an image/case or of looking briefly at, say, the 2D image and being willing not to look at the 3D digital tomosynthesis (DBT) images. The experiment the investigators report here is intended to be a start on studying this issue. There is a continuum of cases from "obviously normal" to "obviously abnormal". The investigators wanted to estimate the point on that continuum below which a case is so normal, that readers would be willing to let the computer triage the case and/or would be willing to triage a case themselves. It is also possible that there are cases so abnormal that the patients can be recalled for further examination by the computer alone though the investigators are not studying that form of triage in this case. The investigators hypothesize that these triage points will be related to both the computer's rating of normality and the reader's rating.

Method: A bilateral 2D mammogram is presented for 5 seconds. The time limit is intended to limit the normal scrutiny that a radiologist would give to the case. The investigators want a decision based on the "gist" of the case. To mimic the low prevalence of disease in a screening mammography, only 4 of 150 cases are positive. Readers are told that the cases mimic a screening setting so they know that positive cases will be rare, but they are not told the actual prevalence.

The investigators ask radiologists to answer two questions about each of up to 150 single image "cases". ("Up to 150" because radiologists can and do quit at without completing all cases. Using a rating scale method, the investigators ask:

  1. How sure are participants that these images are from a normal case? Next the investigators tell readers that "The computer rated these images as X out of 10 (10: highest probability of cancer present)." This AI value is a real rating of abnormality, generated by Transpara version 1.7.0 which returns a probability of malignancy score for the examination. The ratings were obtained by Sarah Verboom of Radboud U. Then the investigators ask the investigators asked if the reader would think that it was reasonable for the computer to triage the case without further human inspection.
  2. How willing would participants be for the computer to make the decision about this case alone without having participants look at it?

Os answered using a sliding bar that served as a rating scale. The selected rating was displayed on top of the sliding bar.

Participants:

The first observers for this study were tested at a 'pop-lab', organized at the European Conference of Radiology (ECR, Vienna, March 2023). The investigators have been organizing these labs as an opportunity for researchers from many labs to come to big meetings like ECR where they might be able to test radiologists in larger numbers than at home. The upside is access to readers. The downside is that the investigators can typically get only 15-30 min of a reader's time. Thus, the readers for this experiment were a population of convenience. The investigators tested 15 readers. These varied widely in experience. The investigators asked how many screening cases they estimated that they read each year. This varied from 0 (students who had learned about mammography but were not in practice) to 8000. Readers also varied in how many cases they were willing to read for us, before running out of time/patience. The range was 19 to 148 (avg 83 cases). At this stage, the investigators are underpowered to say with any conviction if these variables have an important impact of the results. This is a chronic problem with testing experts like radiologists. It is extremely difficult to collect as much data as one would wish. Nevertheless, these data can give us information about the factors that will determine the success or failure of image triage.

Being tested
AI Opinion
Keywords
Mammography, Digital Breast Tomosynthesis, Artificial Intelligence, Radiology, Medical Image Perception

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AI OpinionBehavioural

    For each case, we give the radiologist a numeric score reflecting the AI's rating of the abnormality of the case.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Abnormality rating accuracy

    Readers rate the abnormality of each image. The outcome measure is the agreement with gold standard truth for that case.

    Measured: through study completion, an average of 1 year

  2. AI Acceptance rating

    Readers state if they would accept the AI rating as definitive. The relevant measure is the acceptance rate as a function of AI rating and the human rating of abnormality.

    Measured: through study completion, an average of 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Jul 2023
  2. Study start1 Mar 2023
  3. Primary completion1 Aug 2028 (estimated)
  4. Study completion1 Sep 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Not applicable
Intervention model
Single group
Model description
We are asking the opinions of a group of clinicians.
Masking
Single blind
Who is masked
Participant
Enrolment
16 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05960188
Sponsor's protocol ID
2007P000646-D
Status last verified
Aug 2026
First submitted
14 Jul 2023
Last updated
13 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: We share deidentified on request and, typically, on the Open Science Framework

Questions about this trial

What is this clinical trial studying?

A study testing AI Opinion in people with Breast Cancer Screening, run by Brigham and Women's Hospital at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 13 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Abnormality rating accuracy (time frame: through study completion, an average of 1 year). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in